Association Between Familial Hypercholesterolemia and Prevalence of Type 2 Diabetes Mellitus

被引:300
作者
Besseling, Joost [1 ]
Kastelein, John J. P. [1 ]
Defesche, Joep C. [2 ]
Hutten, Barbara A. [3 ]
Hovingh, G. Kees [1 ]
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Expt Vasc Med, NL-1105 AZ Amsterdam, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol Biostat & Bioinformat, NL-1105 AZ Amsterdam, Netherlands
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2015年 / 313卷 / 10期
关键词
LOW-DENSITY-LIPOPROTEIN; CARDIOVASCULAR-DISEASE; INSULIN-SECRETION; HEART-DISEASE; ABCA1; RISK; CHOLESTEROL; MUTATIONS; PATHOPHYSIOLOGY; METAANALYSIS;
D O I
10.1001/jama.2015.1206
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IMPORTANCE Familial hypercholesterolemia is characterized by impaired uptake of cholesterol in peripheral tissues, including the liver and the pancreas. In contrast, statins increase the cellular cholesterol uptake and are associated with increased risk for type 2 diabetes mellitus. We hypothesize that transmembrane cholesterol transport is linked to the development of type 2 diabetes. OBJECTIVE To assess the association between type 2 diabetes prevalence and familial hypercholesterolemia. DESIGN, SETTING, AND PARTICIPANTS Cross-sectional study in all individuals (n = 63 320) who underwent DNA testing for familial hypercholesterolemia in the national Dutch screening program between 1994 and 2014. EXPOSURES Deleteriousness and nondeleteriousness of familial hypercholesterolemia mutations were based on literature or laboratory function testing. Low-density lipoprotein (LDL) receptor mutations were considered more severe than apolipoprotein B gene (APOB) mutations, and receptor-negative LDL receptor mutations were considered more severe than receptor-deficient mutations. MAIN OUTCOMES AND MEASURES Prevalence of type 2 diabetes. RESULTS The prevalence of type 2 diabetes was 1.75% in familial hypercholesterolemia patients (n = 440/25 137) vs 2.93% in unaffected relatives (n = 1119/38 183) (P <.001; odds ratio [OR], 0.62 [95% CI, 0.55-0.69]). The adjusted prevalence of type 2 diabetes in familial hypercholesterolemia, determined using multivariable regression models, was 1.44% (difference, 1.49% [95% CI, 1.24%-1.71%]) (OR, 0.49 [95% CI, 0.41-0.58]; P <.001). The adjusted prevalence of type 2 diabetes by APOB vs LDL receptor gene was 1.91% vs 1.33% (OR, 0.65 [95% CI, 0.48-0.87] vs OR, 0.45 [95% CI, 0.38-0.54]), and the prevalence for receptor-deficient vs receptor-negative mutation carriers was 1.44% vs 1.12%(OR, 0.49 [95% CI, 0.40-0.60] vs OR, 0.38 [95% CI, 0.29-0.49]), respectively (P for trend <. 001 in both comparisons). CONCLUSIONS AND RELEVANCE In a cross-sectional analysis in the Netherlands, the prevalence of type 2 diabetes among patients with familial hypercholesterolemia was significantly lower than among unaffected relatives, with variability by mutation type. If this finding is confirmed in longitudinal analysis, it would raise the possibility of a causal relationship between LDL receptor-mediated transmembrane cholesterol transport and type 2 diabetes.
引用
收藏
页码:1029 / 1036
页数:8
相关论文
共 37 条
[1]   Cardiovascular disease in familial hypercholesterolaemia: Influence of low-density lipoprotein receptor mutation type and classic risk factors [J].
Alonso, R. ;
Mata, N. ;
Castillo, S. ;
Fuentes, F. ;
Saenz, P. ;
Muniz, O. ;
Galiana, J. ;
Figueras, R. ;
Diaz, J. L. ;
Gomez-Enterria, P. ;
Mauri, M. ;
Piedecausa, M. ;
Irigoyen, L. ;
Aguado, R. ;
Mata, P. .
ATHEROSCLEROSIS, 2008, 200 (02) :315-321
[2]   Statins and Diabetes: The Good, the Bad, and the Unknown [J].
Axsom, Kelly ;
Berger, Jeffrey S. ;
Schwartzbard, Arthur Z. .
CURRENT ATHEROSCLEROSIS REPORTS, 2013, 15 (02)
[3]  
Bertolini S, 2000, ARTERIOSCLER THROMB, V20, P41
[4]   Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy [J].
Bertolini, Stefano ;
Pisciotta, Livia ;
Rabacchi, Claudio ;
Cefalu, Angelo B. ;
Noto, Davide ;
Fasano, Tommaso ;
Signori, Alessio ;
Fresa, Raffaele ;
Averna, Maurizio ;
Calandra, Sebastiano .
ATHEROSCLEROSIS, 2013, 227 (02) :342-348
[5]   Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: A study of a cohort of 14,000 mutation carriers [J].
Besseling, Joost ;
Kindt, Iris ;
Hof, Michel ;
Kastelein, John J. P. ;
Hutten, Barbara A. ;
Hovingh, G. Kees .
ATHEROSCLEROSIS, 2014, 233 (01) :219-223
[6]   Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials [J].
Boussageon, Remy ;
Bejan-Angoulvant, Theodora ;
Saadatian-Elahi, Mitra ;
Lafont, Sandrine ;
Bergeonneau, Claire ;
Kassai, Behrouz ;
Erpeldinger, Sylvie ;
Wright, James M. ;
Gueyffier, Francois ;
Cornu, Catherine .
BMJ-BRITISH MEDICAL JOURNAL, 2011, 343
[7]   β-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment [J].
Brunham, Liam R. ;
Kruit, Janine K. ;
Pape, Terry D. ;
Timmins, Jenelle M. ;
Reuwer, Anne Q. ;
Vasanji, Zainisha ;
Marsh, Brad J. ;
Rodrigues, Brian ;
Johnson, James D. ;
Parks, John S. ;
Verchere, C. Bruce ;
Hayden, Michael R. .
NATURE MEDICINE, 2007, 13 (03) :340-347
[8]   Low density lipoprotein can cause death of islet β-cells by its cellular uptake and oxidative modification [J].
Cnop, M ;
Hannaert, JC ;
Grupping, AY ;
Pipeleers, DG .
ENDOCRINOLOGY, 2002, 143 (09) :3449-3453
[9]  
COBBAERT C, 1994, EUR J CLIN CHEM CLIN, V32, P391
[10]   Clinical characteristics of patients with type 2 diabetes mellitus at the time of insulin initiation: INSTIGATE observational study in Spain [J].
Costi, Maria ;
Dilla, Tatiana ;
Reviriego, Jesus ;
Castell, Conxa ;
Goday, Albert .
ACTA DIABETOLOGICA, 2010, 47 :S169-S175